Blackstone and TPG Aim to Sell Hologic's Surgical Unit for $4 Billion

Private equity giants Blackstone and TPG are reportedly seeking to sell the surgical division of medical technology firm Hologic for more than $4 billion. This move comes as both firms work with advisers on the sale of the division, which is known for its surgical equipment used by gynecologists, according to a report by the Financial Times.

The surgical unit is part of Hologic, a company that Blackstone and TPG acquired last year in a deal valued at $18.3 billion, one of the largest buyouts in the medical device sector. The acquisition was completed in April 2026, involving a combination of cash and debt.

Strategic Financial Moves

The potential sale of the surgical unit appears to be a strategic decision by Blackstone and TPG to manage their financial obligations. The firms aim to reduce debt and return funds to their investors following the significant outlay involved in the Hologic acquisition. This move is seen against a backdrop of challenges in the private credit market, which have had a ripple effect on private equity firms, encouraging them to seek ways to ensure liquidity and investor returns.

Blackstone has recently faced pressure from redemption requests, prompting it to limit withdrawals from its flagship private credit fund. This situation underscores the broader financial dynamics currently influencing private equity markets, where maintaining liquidity and investor confidence are key priorities.

Market Implications

The sale of Hologic's surgical unit, if successful, could provide insights into the current valuation trends within the medical technology sector. The unit's focus on gynecological surgical equipment places it in a niche market with specific demand dynamics. Potential buyers may view the acquisition as an opportunity to capitalize on the specialized equipment and the established market presence of Hologic's surgical division.

Neither Blackstone, TPG, nor Hologic have commented on the report outside of normal business hours, and Reuters has not independently verified the Financial Times' report. Nonetheless, the potential transaction highlights the ongoing adjustments within private equity as firms navigate economic pressures and seek to optimize their investment portfolios.

Should the sale proceed, it would mark another significant chapter in the evolving ownership and operational strategies of major players in the medical technology field, reflecting broader trends in how private equity firms manage their assets amid changing market conditions.